Even if Wall Street scratches off the soon-to-report, longshot phase III SEAMLESS trial in acute myeloid leukemia (AML), Cyclacel Pharmaceuticals Inc. may have value aplenty in an early stage pair of other clinical programs. But home-run hopes die hard and biotech is full of surprises – such as Vyxeos, the late-stage AML winner in March for Celator Pharmaceuticals Inc.